CompletedPHASE1, PHASE2NCT00963534
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lund University Hospital
- Principal Investigator
- Mats Jerkeman, MD, PhDUniversity Hospital Lund, Sweden
- Intervention
- lenalidomide, bendamustine, rituximab(drug)
- Enrollment
- 51 target
- Eligibility
- 65 years · All sexes
- Timeline
- 2009 – 2017
Study locations (17)
- Århus University Hospital, Aarhus, Denmark
- Herlev Hospital, Copenhagen, Denmark
- Rigshospitalet, Department of Hematology, Copenhagen, Denmark
- Helsinki University Central Hospital, Helsinki, Finland
- Haukeland University Hospital, Department of Oncology, Bergen, Norway
- Norwegian Radium Hospital, Oslo, Norway
- Ulleval University Hospital, Department of Oncology, Oslo, Norway
- University Hospital of Stavanger, Department of Haematology and Oncology, Stavanger, Norway
- University Hospital of Tromso, Department of Oncology, Tromsø, Norway
- Sahlgrenska University Hospital, Department of Hematology, Gothenburg, Sweden
- University Hospital Linköping, Department of Hematology, Linköping, Sweden
- Sunderbyn Hospital, Department of Medicine, Luleå, Sweden
- University Hospital Lund, Department of Oncology, Lund, Sweden
- Karolinska University Hospital, Department of Hematology, Stockholm, Sweden
- Sundsvall Hospital, Department of Medicine, Sundsvall, Sweden
- +2 more locations on ClinicalTrials.gov
Collaborators
Mundipharma Pte Ltd. · Celgene · Roche Pharma AG
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00963534 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University
- RECRUITINGPHASE3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)BeOne Medicines
- RECRUITINGNCT06788652A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06522386GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center